SOHO State of the Art Updates and Next Questions | Novel Approaches to Pediatric T-cell ALL and T-Lymphoblastic Lymphoma.
Clin Lymphoma Myeloma Leuk
; 22(10): 718-725, 2022 10.
Article
en En
| MEDLINE
| ID: mdl-35941070
ABSTRACT
While outcomes for children with T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL) have improved significantly with contemporary therapy, outcomes for patients with relapsed or refractory (r/r) disease remain dismal. Improved risk stratification and the incorporation of novel therapeutics have the potential to improve outcomes further in T-ALL/T-LL by limiting relapse risk and improving salvage rates for those with r/r disease. In this review we will discuss the challenges and new opportunities for improved risk stratification in T-ALL and T-LL. We will further discuss the recent incorporation of the novel therapeutics nelarabine and bortezomib into front-line therapy for children with T-ALL and T-LL. Finally, we will address new classes of targeted small molecule inhibitors, immunotherapeutics, and chimeric antigen receptor T-cell therapies under investigation in r/r T-ALL and T-LL.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Linfoma no Hodgkin
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Leucemia-Linfoma Linfoblástico de Células T Precursoras
/
Receptores Quiméricos de Antígenos
Límite:
Child
/
Humans
Idioma:
En
Revista:
Clin Lymphoma Myeloma Leuk
Asunto de la revista:
NEOPLASIAS
Año:
2022
Tipo del documento:
Article
País de afiliación:
Gabón